Real-World Dosing and Persistence of Oral Treprostinil Initiation Strategies in Patients With Pulmonary Arterial Hypertension.

ABSTRACT: In patients with pulmonary arterial hypertension (PAH), limited real-world data are available on persistence to oral treprostinil therapy, particularly while transitioning from parenteral prostacyclins. We compared persistence to oral treprostinil and total daily dose (TDD) achieved among patients with PAH initiating oral treprostinil de novo or while transitioning from parenteral prostacyclins using two real-world datasets: specialty pharmacy shipment records (Analysis 1) and ADAPT registry (Analysis 2). In Analysis 1, patients receiving oral treprostinil in 2017, 2020, and 2023 were included. In Analysis 2, de-identified data of patients enrolled in ADAPT from July 2017 to January 2022 were included. We conducted descriptive analyses and quantified persistence to oral treprostinil and TD

SUBMITTER: Lachant DJ 

PROVIDER: S-EPMC12717468 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature